
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma is supported by an increasingly differentiated ADC platform, led by STRO-004’s early clinical signals of activity across PDAC, HNSCC, and NSCLC in 49 heavily pretreated patients, alongside a favorable safety/PK profile with a 6% discontinuation rate, nearly seven-day half-life, and low free exatecan exposure. The company’s pipeline breadth strengthens the long-term thesis, as STRO-006 is expected to enter Ph 1 in 3Q26 and STRO-227 is on track for an IND submission in 2026, while preclinical data suggest superior antitumor activity and feasibility for dual-payload delivery. Financially, Sutro ended 2Q26 with $164.3MM in cash, cash equivalents, and marketable securities, which management expects to fund operations into at least 2Q28, giving it runway to advance multiple programs.
Bears say
Sutro Biopharma is a high-risk clinical-stage developer whose value depends heavily on unproven ADC assets, making the investment case vulnerable to trial failure if efficacy or safety fall short in current or future studies. Its outlook is further pressured by regulatory and commercial uncertainty, since approval from the FDA and foreign agencies is not guaranteed and delays would likely impair commercialization, while dependence on partners adds another layer of execution risk. Despite being well-funded with cash, cash equivalents, and short-term investments, it may still need additional equity financing to complete development, and intense competition from larger biotechnology and pharmaceutical rivals could erode market opportunity.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Sutro Biopharma Inc (STRO) Forecast
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares